A phase I first-in-human study of REGN910 (SAR307746), a fully human and selective angiopoietin-2 (Ang2) monoclonal antibody (MAb), in patients with advanced solid tumor malignancies.

被引：0
|
作者：
Papadopoulos, Kyriakos P.
Sahebjam, Solmaz
Kelley, Robin Katie
Tolcher, Anthony W.
Razak, Albiruni R. A.
Patnaik, Amita
Bedard, Philippe L.
Arcos, Rebecca
Adriaens, Lieve
Brownstein, Carrie M.
Lowy, Israel
Gao, Bo
DiCioccio, A. Thomas
Trail, Pamela
Siu, Lillian L.
机构：
[1] START Ctr Canc Care, San Antonio, TX USA
[2] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada
[3] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA
[4] South Texas Accelerated Res Therapeut LLC, San Antonio, TX USA
[5] Univ Toronto, Dept Med, Div Med Oncol & Hematol, Princess Margaret Canc Ctr,Univ Hlth Network, Toronto, ON, Canada
[6] Regeneron Pharmaceut Inc, Tarrytown, NY USA
[7] Princess Margaret Canc Ctr, Toronto, ON, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2517
引用
收藏
页数：1
相关论文
共 50 条
  • [21] First-in-human, phase I, dose-escalation study of selective PI3Kα isoform inhibitor MLN1117 in patients (pts) with advanced solid malignancies.
    Juric, Dejan
    De Bono, Johann Sebastian
    LoRusso, Patricia
    Nemunaitis, John J.
    Heath, Elisabeth I.
    Kwak, Eunice Lee
    Macarulla, Teresa
    Geuna, Elena
    Luken, Maria Jose de Miguel
    Patel, Chirag
    Kuida, Keisuke
    Sankoh, Serap
    Zohren, Fabian
    Shou, Yaping
    Tabernero, Josep
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [22] First-in-human, phase I study of AK109, an anti-VEGFR2 antibody in patients with advanced or metastatic solid tumors
    Zheng, Y.
    Zhong, H.
    Zhao, F.
    Zhou, H.
    Mao, C.
    Lv, W.
    Yuan, M.
    Qian, J.
    Jiang, H.
    Wang, Z.
    Xiao, C.
    Guo, J.
    Liu, T.
    Liu, W.
    Wang, Z. M.
    Li, B.
    Xia, M.
    Xu, N.
    ESMO OPEN, 2023, 8 (02)
  • [23] A first-in-human, multicenter, open-label, phase 1 study of ATOR-1017, a 4-1BB antibody, in patients with advanced solid malignancies.
    Ullenhag, Gustav J.
    Yachnin, Jeffrey
    Carneiro, Ana
    Elison, Emma
    Carlsson, Malin
    Russell, Charlotte Astrid
    Smith, Karin Enell
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [24] First-in-human study of AMG 386, a selective angiopoietin1/2-neutralizing peptibody, in adult patients with advanced solid tumors
    Rosen, L. S.
    Hong, D.
    Chap, L.
    Kurzrock, R.
    Garcia, A.
    Rasmussen, E.
    Nguyen, L.
    Hwang, Y.
    Storgard, C.
    Herbst, R. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [25] A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors
    Sandhu, Shahneen K.
    Papadopoulos, Kyri
    Fong, Peter C.
    Patnaik, Amita
    Messiou, Christina
    Olmos, David
    Wang, George
    Tromp, Brenda J.
    Puchalski, Thomas A.
    Balkwill, Frances
    Berns, Birge
    Seetharam, Shobha
    de Bono, Johann S.
    Tolcher, Anthony W.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (04) : 1041 - 1050
  • [26] A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors
    Shahneen K. Sandhu
    Kyri Papadopoulos
    Peter C. Fong
    Amita Patnaik
    Christina Messiou
    David Olmos
    George Wang
    Brenda J. Tromp
    Thomas A. Puchalski
    Frances Balkwill
    Birge Berns
    Shobha Seetharam
    Johann S. de Bono
    Anthony W. Tolcher
    Cancer Chemotherapy and Pharmacology, 2013, 71 : 1041 - 1050
  • [27] A first-in-human phase I study of SAR125844, a selective MET tyrosine kinase inhibitor, in patients with advanced solid tumours with MET amplification
    Angevin, Eric
    Spitaleri, Gianluca
    Rodon, Jordi
    Dotti, Katia
    Isambert, Nicolas
    Salvagni, Stefania
    Moreno, Victor
    Assadourian, Sylvie
    Gomez, Corinne
    Harnois, Marzia
    Hollebecque, Antoine
    Azaro, Analia
    Hervieu, Alice
    Rihawi, Karim
    De Marinis, Filippo
    EUROPEAN JOURNAL OF CANCER, 2017, 87 : 131 - 139
  • [28] First-in-Human Phase I Study of Single-agent Vanucizumab, A First-in-Class Bispecific Anti-Angiopoietin-2/Anti-VEGF-A Antibody, in Adult Patients with Advanced Solid Tumors
    Hidalgo, Manuel
    Martinez-Garcia, Maria
    Le Tourneau, Christophe
    Massard, Christophe
    Garralda, Elena
    Boni, Valentina
    Taus, Alvaro
    Albanell, Joan
    Sablin, Marie-Paule
    Alt, Marie
    Bahleda, Ratislav
    Varga, Andrea
    Boetsch, Christophe
    Franjkovic, Izolda
    Heil, Florian
    Lahr, Angelika
    Lechner, Katharina
    Morel, Anthony
    Nayak, Tapan
    Rossomanno, Simona
    Smart, Kevin
    Stubenrauch, Kay
    Krieter, Oliver
    CLINICAL CANCER RESEARCH, 2018, 24 (07) : 1536 - 1545
  • [29] A first-in-human (FIH) phase I study of IPH5301, an anti-CD73 monoclonal antibody (mAb), in patients with advanced solid tumors (AST) (CHANCES, NCT05143970)
    Beaufils, M.
    Mailliez, A.
    Sfumato, P.
    Vicier, C.
    Gross, M. Provansal
    Guerin, M.
    Chanez, B.
    Kotecki, N.
    Widemann, A.
    Panzolato, S.
    Chammard, A. Boyer
    Andre, P.
    Paturel, C. L.
    Gouarne, C.
    Awada, A. H.
    Boher, J. M.
    Goncalves, A.
    ANNALS OF ONCOLOGY, 2024, 35 : S682 - S683
  • [30] A phase I first-in-human study of PRTH-101, an IgG1 monoclonal antibody targeting DDR1, as a monotherapy and combined with pembrolizumab in patients with advanced solid malignancies
    Sen, S.
    Spira, A. I.
    Sommerhalder, D.
    Meric-Bernstam, F.
    Subbiah, V.
    Berlin, J. D.
    Parikh, A.
    Cecchini, M.
    Sanborn, R. E.
    Chablani, P. V.
    Peoples, G. E.
    Schurpf, T.
    Dillon, L. A.
    Clifton, G. T.
    Eder, J. P.
    Tolcher, A. W.
    ANNALS OF ONCOLOGY, 2023, 34 : S649 - S650
12345